Muscle on a GLP-1: how much of the weight lost is lean mass?

Reviewed 10 sourcesPublished by PepVault

How much weight lost on a GLP-1 is lean mass: SURMOUNT-1, STEP 1, the apitegromab and bimagrumab add-on trials, and what guidance says on protein and training.

A woman with auburn hair doing a one-arm dumbbell row on a padded bench in a bright home gym
Last reviewed
Sources
10
Questions
7
Compounds
4

The short answer

In the trials, about a quarter to two-fifths of the weight lost on tirzepatide or semaglutide was lean mass, roughly the share any large weight loss takes, and lean mass is more than muscle. The 2025 nutrition advisory pairs the drug with protein, 1.2 to 1.6 g per kg a day proposed during active weight loss, and strength training at least three times a week.

Every number checked at its primary source · · 10 sources · How we research

Evidence: Randomised trials in people: DXA substudies of the phase 3 SURMOUNT-1 and STEP 1 trials, the phase 2 BELIEVE and EMBRAZE add-on trials, and a one-year liraglutide and exercise trial, a phase 2 retatrutide DXA substudy, plus a 2025 joint advisory and a 2026 review; tirzepatide, semaglutide and liraglutide are FDA-approved for weight management, apitegromab is FDA-approved only for spinal muscular atrophy, and bimagrumab and retatrutide are investigational.

A woman with auburn hair doing a one-arm dumbbell row on a padded bench in a bright home gym

How much of the weight lost on a GLP-1 is lean mass?

Most of it is fat. In the body-composition substudy of SURMOUNT-1, 160 people had a DXA scan (a low-dose X-ray scan that splits the body into fat, bone and everything else) at the start and after 72 weeks. On tirzepatide, fat mass fell 33.9% and lean mass 10.9%, against 8.2% and 2.6% on placebo. Of the weight lost, 74% was fat and 26% lean on tirzepatide, and 75% and 25% on placebo1.

Semaglutide's trials put the lean share higher. In STEP 1's DXA group, people on 2.4 mg lost 9.3 kg of fat and 5.8 kg of lean mass by week 682, about 38% of the tissue lost, the figure the 2025 nutrition advisory gives for the same trial6. Lilly's BELIEVE trial, with semaglutide 2.4 mg as one of its arms, measured about 29% at week 4834. The table lines the trials up.

Trial and groupWeight lostLean mass lostLean share of the loss
SURMOUNT-1, tirzepatide 5 to 15 mg, 72 weeks21.3%5.6 kg (10.9%)26%1
SURMOUNT-1, placebo, 72 weeks5.3%1.2 kg (2.6%)25%1
STEP 1, semaglutide 2.4 mg, 68 weeks15.5 kg5.8 kgAbout 38%26
BELIEVE, semaglutide 2.4 mg alone, 48 weeks14.2 kg4.4 kgAbout 29%34
BELIEVE, bimagrumab plus semaglutide 2.4 mg, 48 weeks17.8 kg1.4 kgAbout 8%34
EMBRAZE, tirzepatide with placebo, 24 weeks12.5 kg3.5 kg30.2%5
EMBRAZE, tirzepatide with apitegromab, 24 weeks11.2 kg1.6 kg14.6%5
Stacked bars of where the weight went, each to 100%: lean mass was 26% of the loss on tirzepatide in SURMOUNT-1, 25% on its placebo, about 38% on semaglutide in STEP 1, 29% in BELIEVE, 8% with bimagrumab, 30.2% in EMBRAZE and 14.6% with apitegromab
Look at the lean segment: a quarter to two-fifths on the GLP-1 drugs alone, the same quarter on SURMOUNT-1's placebo, and smaller in the two add-on arms.

The shares are not a straight drug-to-drug comparison: the trials ran for different lengths of time in different people, and BELIEVE reports the fat share of fat plus lean loss (the lean share here is the remainder)3. For STEP 1, the share is lean mass over the fat and lean mass lost2; SURMOUNT-1's paper, working from STEP 1's main publication, puts it at 40%1.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault, Food sets your daily protein target; on a weight-loss goal it is 1.6 g per kg of your goal weight while you are above it.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Is lean mass the same as muscle?

No. On a DXA scan, lean mass is everything that is neither fat nor bone: skeletal muscle, but also the organs, connective tissue, body water and the water stored with glycogen, the body's carbohydrate reserve. So a drop in lean mass is not a one-to-one measure of muscle lost, and early changes partly reflect water and glycogen8. SURMOUNT-1's paper defines it the same way, as fat-free mass minus bone1.

Muscle is about half of lean body mass, so the advisory reads STEP 1's 38% lean share as roughly 20% of the weight lost being muscle6. The scan also misses what it cannot see: it does not measure fat inside the muscle or how strong the muscle is, which is why a 2026 review judges muscle on mass, strength and quality together8.

Body weight split into fat, bone and lean soft tissue; the lean block opens into skeletal muscle, about half of it, and organs, connective tissue, and water and glycogen
A DXA scan's 'lean mass' is the whole right-hand block. Muscle is only part of it.

Do GLP-1s take more muscle than an ordinary diet?

By share, no. Everyone in SURMOUNT-1 had diet and activity counselling, aiming at a 500 kcal daily deficit and 150 minutes of activity a week with no strength programme. The placebo group, on that advice alone, lost the same quarter as lean mass as the tirzepatide group did, while losing far less weight1. The split held across sex, age and size of weight loss, at 70 to 76% fat with tirzepatide in every subgroup1. The advisory notes the losses track the amount of weight lost and match what bariatric surgery and very low-calorie diets do6. Retatrutide, an investigational triple agonist, looks the same so far: in its 36-week DXA substudy in people with type 2 diabetes, the lean share of the weight lost was similar to other obesity treatments10.

What does grow is the amount, because more weight comes off. In SURMOUNT-1, 5.6 kg of lean mass went with tirzepatide against 1.2 kg on placebo1. The advisory adds that the loss also depends on how hard calories are cut, how fast the weight comes off, and whether you strength-train6.

Does losing lean mass make you weaker?

The trials so far have not shown it. People on tirzepatide in SURMOUNT-1 reported better physical function despite the lean mass they lost1. The flip side holds too: the add-on drugs below kept lean mass, yet in BELIEVE grip strength on the high-dose combination rose no more than on placebo, and only one combination group (bimagrumab with semaglutide 1.0 mg) gained significantly3, while EMBRAZE saw no notable difference in physical function5.

The concern is sharper for some people. The advisory names older age, perimenopause or menopause, lower testosterone, sitting most of the day, low protein intake and no strength training as raising the risk of muscle loss6, and SURMOUNT-1's authors flag older adults with, or at risk of, sarcopenic obesity, which is low muscle alongside excess fat1. If everyday things such as stairs or getting up from a chair get harder while the weight comes off, raise it with your prescriber.

What did the apitegromab and bimagrumab trials try?

Both add a muscle-sparing antibody to the weight-loss drug, and neither is approved for weight loss or for muscle on a GLP-1. Bimagrumab is investigational; apitegromab's one approval, from September 2026, is for spinal muscular atrophy, a rare inherited muscle-wasting disease9. Apitegromab blocks the activation of myostatin, a growth factor that regulates the breakdown of skeletal muscle5. In EMBRAZE, a phase 2 trial in 102 adults, everyone took tirzepatide and half also had apitegromab. At week 24 weight loss was similar, but the apitegromab group lost 1.6 kg of lean mass against 3.5 kg, keeping 1.9 kg more, which the authors call 54.9% retention5. Eight weeks after both drugs stopped, the gap was 0.9 kg5.

Bimagrumab blocks the type II activin receptors, which carry myostatin's signal and the signal from activin A3. BELIEVE randomised 507 adults to nine groups, mixing bimagrumab, semaglutide and placebo. At week 48 the high-dose combination took off 17.8 kg against 14.2 kg on semaglutide 2.4 mg alone, and 92.3% of the fat and lean mass lost was fat, against 71.1%34. Bimagrumab alone added a little lean mass3. Muscle spasms, diarrhoea and acne were its common side effects3.

Do protein and exercise protect muscle on a GLP-1?

Training is the better-supported half. Structured strength training, alone or mixed with aerobic work, is well established to help keep lean mass during weight loss, and aerobic exercise alone does less6. The advisory is blunt on protein: more of it alone is likely not enough to keep muscle without structured resistance training6.

One randomised trial of a GLP-1 plus exercise used liraglutide, an older daily GLP-1. After an eight-week low-calorie diet, 195 adults spent a year on exercise, liraglutide, both or neither. The combination lowered body-fat percentage by 3.9 points, about twice either one alone, and only the combination improved insulin sensitivity and fitness7. Its exercise was a moderate-to-vigorous programme, and its body-composition end point was body-fat percentage, not muscle7.

Commonly reported: protein being the hardest target to reach when appetite is low, eating the protein part of a meal first or using shakes and yoghurt to close the gap, and lifts holding steady in the gym while the scale keeps dropping.

How much protein and training does the guidance propose?

These are the 2025 joint advisory's figures for people taking GLP-1 medicines, from four US obesity and nutrition societies: published ranges, not a prescription6.

  1. Find your protein range: the advisory lists 0.8 g per kg a day as the adult allowance and 1.2 to 1.6 g per kg a day as proposed during active weight loss6. The GLP-1 protein calculator on this site does the sum from the weight you type in: set to 200 lb (91 kg) and "Losing weight", it multiplies by 1.2 and 1.6 and gives 109 to 145 g a day. With obesity, your actual weight can overstate the need, and the advisory leaves open which weight to use6.
  2. If counting per kg is a chore, use the advisory's simpler absolute target of 80 to 120 g a day6.
  3. Eat the protein part of each meal first, so it goes in before your appetite runs out6.
  4. Keep your intake between the advisory's bounds: not below 0.4 to 0.5 g per kg a day, and not at 2 g per kg a day or more for long periods6.
  5. Plan strength training at least three times a week, plus at least 150 minutes of moderate aerobic exercise, matched to your fitness level, which is what the advisory aims for alongside the drug6.
Two ranges of daily protein: 109 to 145 g from the per-kg rule at 200 lb while losing weight, and the advisory’s simpler 80 to 120 g
The per-kg range and the advisory's simpler absolute target, side by side.

In PepVault, Food sets your daily protein target; on a weight-loss goal it is 1.6 g per kg of your goal weight while you are above it. Track your food in PepVault

Training holds your weekly plan and logs each session you do, so the three strength days are on the page. Log it in PepVault

Track it in the app

Sources

  1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. Correction (Figure 4's axis label): 2025;27(11):6823. PubMed 39996356
  2. Novo Nordisk A/S. STEP 1: semaglutide 2.4 mg in people with overweight or obesity (NCT03548935). ClinicalTrials.gov results: body composition by DXA, baseline to week 68. clinicaltrials.gov
  3. Heymsfield SB, Aronne LJ, Montgomery P, et al.; BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026;32(3):869-882. PubMed 41772149
  4. Eli Lilly and Company. Safety and efficacy of bimagrumab and semaglutide in adults who are overweight or obese (BELIEVE, NCT05616013). ClinicalTrials.gov results: body weight and lean mass by DXA at week 48. clinicaltrials.gov
  5. Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial (EMBRAZE). Nat Med. 2026;32(7):2673-2678. PubMed 42260100
  6. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity. 2025;33(8):1475-1503. PubMed 40445127
  7. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730. PubMed 33951361
  8. Kim JY, Kim NH. Beyond fat loss: addressing the sarcopenia challenge of incretin-based therapies. Diabetes Metab J. 2026;50(5):844-862. PubMed 42722378
  9. Scholar Rock, Inc. ISEMBYLD (apitegromab-mstn) injection, prescribing information (DailyMed, version 3, Sep 2026): indicated for spinal muscular atrophy; initial US approval 2026. dailymed.nlm.nih.gov
  10. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PubMed 40609566

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo